Larotrectinib monotherapy with 131I therapy for Pediatric Cancer

"Indeed, information from clinicaltrials.gov shows that this investigation is currently open to enrollment. This trial was initially listed on February 14th, 2024 and last modified on February 15th, 2024. The study aims to recruit a total of 13 participants across one site."

"The safety assessment for Larotrectinib monotherapy combined with 131I therapy is rated at 2 by our team, denoting a Phase II trial status. At this stage, there exists preliminary data regarding safety aspects but not yet on efficacy outcomes."

"The trial seeks 13 participants aged between 2 and 99 with thyroid cancer. Eligible candidates must meet the subsequent requirements: age ≥ 1 year, confirmed histologic diagnosis of differentiated thyroid cancer, post-thyroidectomy status along with sufficient local therapy for neck metastatic disease per treating investigator’s judgment either showing multiple (>10) noncalcified solid pulmonary nodules on CT or displaying enlarging discrete pulmonary nodules consistent with metastatic ailment; presence of neurotrophic tyrosine receptor kinase (NTRK) gene fusion validated in a CLIA/CAP accredited laboratory without known resistance mutation within the kinase domain; performance"

"Eligible participants for this research endeavor range from 2 to 99 years old. Specifically, there are 130 ongoing clinical trials catering to individuals under the age of 18 and another 685 dedicated to those above the age of 65."

"Indeed, the details on clinicaltrials.gov reveal that this trial is actively pursuing volunteers. Initially shared on February 14th, 2024, and last revised on February 15th, 2024, the study aims to enroll 13 participants at a single site."